STAR Clinical Trial

The STAR clinical trial, involving 126 Obstructive Sleep Apnea (OSA) patients across the United States and Europe, began in 2010 to evaluate the safety and efficacy of Inspire therapy. One-year STAR Trial results were published in the New England Journal of Medicine3, in January 2014, and Inspire therapy received approval by the United States Food and Drug Administration (FDA) in April of that year.

STAR clinical trial 5-year outcomes1 show that sleep apnea patients receiving Inspire therapy experienced significant and sustained reductions in sleep apnea events and significant improvements in both quality of life and daytime functioning*, as measured by various questionnaires.